Pantoprazol, Pakningsstørrelser > 28 Stk. Stada (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazol, Pakningsstørrelser > 28 Stk. Stada, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults.

GNH USA supplies Pantoprazol, Pakningsstørrelser > 28 Stk. Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with this rare neuroendocrine tumor. - Maintenance therapy after healed erosive esophagitis: helps prevent relapse of symptoms. - Prevention of NSAID‑induced gastric ulcers: reduces the risk of ulcer formation in patients requiring long‑term NSAID therapy.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools, usually transient. - Abdominal pain: cramping or discomfort. - Nausea: occasional feeling of queasiness. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Acute interstitial nephritis: inflammation of the kidneys. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: severe diarrhea linked to gut flora disruption. - Osteoporosis‑related fractures: increased risk with long‑term use. - Hypomagnesemia: low magnesium levels, potentially causing muscle cramps or arrhythmias.

Before initiating pantoprazole therapy, consider the following safety measures: - Assess renal function: dose adjustment may be needed in severe impairment. - Review liver status: monitor for rare hepatic effects. - Evaluate need for long‑term use: limit duration to the shortest effective period. - Monitor electrolytes: especially magnesium during prolonged therapy. - Caution in pregnancy: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Pantoprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Antiretroviral protease inhibitors (e.g., atazanavir, nelfinavir): reduced absorption and efficacy. - Antifungal agents (e.g., ketoconazole, itraconazole): markedly decreased bioavailability. - Clopidogrel: diminished antiplatelet activity, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, requiring more frequent monitoring. - Methotrexate (high dose): possible increased serum concentrations. - Digoxin: slight increase in serum levels, monitor for toxicity.